The news comes as industry analysts begin to question the events surrounding Scheuble's departure. One theory put forward places Scheuble at the centre of a disagreement with the Merck family over the firm's future strategy.
"Given the suddenness of his departure, we would surmise that Dr Scheuble had a falling-out with the Merck family," said investment firm Nomura in a report.
Another theory suggested that Scheuble's differences with the Merck family were not over strategy, but the sceptical nature of its investors, who were concerned over upheaval elsewhere in the sector.
Analysts reckoned that Merck may be reviewing their strategic options in a wave of corporate soul-searching that could trigger more healthcare mergers and acquisitions.
The Merck family hold a controlling 73 per cent stake in the business, most widely known for its treatments for cancer, heart disease and diabetes.
In the process, Merck have named Michael Roemer as the new chairman of the executive board with immediate effect.
Elmar Schnee joins the executive board and will be responsible for the Pharmaceutical Business Sector.
